The Experts below are selected from a list of 300 Experts worldwide ranked by ideXlab platform
Jeffrey E. Gershenwald - One of the best experts on this subject based on the ideXlab platform.
-
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care.
Expert review of anticancer therapy, 2018Co-Authors: Emily Z. Keung, Jeffrey E. GershenwaldAbstract:Introduction: The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January 2018.Areas covered: This article provides...
-
revised american Joint Committee on cancer staging criteria accurately predict sentinel lymph node positivity in clinically node negative melanoma patients
Annals of Surgical Oncology, 2003Co-Authors: Dennis L Rousseau, Merrick I Ross, Marcella M Johnson, Victor G Prieto, Jeffrey E Lee, Paul F Mansfield, Jeffrey E. GershenwaldAbstract:Background: The American Joint Committee on Cancer (AJCC) has recently modified staging criteria for primary melanoma patients and recommends sentinel lymph node (SLN) biopsy in many because microscopic nodal metastasis represents the most important factor predicting survival. The purpose of this study was to correlate the incidence of SLN metastasis with revised AJCC staging.
-
final version of the american Joint Committee on cancer staging system for cutaneous melanoma
Journal of Clinical Oncology, 2001Co-Authors: Charles M Balch, Jeffrey E. Gershenwald, Daniel G Coit, Antonio C Buzaid, Seng Jaw Soong, Michael B Atkins, Natale Cascinelli, Irvin D Fleming, Alan N Houghton, J M KirkwoodAbstract:PURPOSE: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS: The prognostic factors analysis described in the companion publication (this issue), as well as evidence from the published literature, was used to assemble the tumor-node-metastasis criteria and stage grouping for the melanoma staging system. RESULTS: Major changes include (1) melanoma thickness and ulceration but not level of invasion to be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, microscopic) versus clinically apparent (ie, macroscopic) nodal metastases to be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase to be used in the M category; (4) an upstaging of all patients with stage I, II, and III disease when a primary melanoma is ulcerated; (5) a merging of sa...
Swathi Kaliki - One of the best experts on this subject based on the ideXlab platform.
-
Ocular surface squamous neoplasia: analysis based on the 8th American Joint Committee on Cancer classification.
International ophthalmology, 2018Co-Authors: Swati Singh, Ashik Mohamed, Swathi KalikiAbstract:Purpose To evaluate outcomes of ocular surface squamous neoplasia (OSSN) based on American Joint Committee on Cancer (AJCC), 8th edition classification.
-
Reply re: "American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes".
Ophthalmic Plastic and Reconstructive Surgery, 2012Co-Authors: Carol L Shields, Swathi Kaliki, Sara E Lally, Saad A Al-dahmash, Jerry A ShieldsAbstract:PURPOSE The aim of this study was to evaluate conjunctival melanoma outcomes based on American Joint Committee on Cancer classification. The study design constituted a nonrandomized interventional case series. METHODS This was a retrospective chart review comprising 343 participants, and the main outcome measures were melanoma local recurrence, lymph node metastasis, distant metastasis, and death. RESULTS On the basis of the American Joint Committee on Cancer classification (seventh edition), conjunctival melanoma was classified as T1 (196 [57%]), T2 (110 [32%]), T3 (37 [11%]), and T4 (0). The mean tumor basal diameter increased with tumor staging with 8.5 mm for T1, 12.7 mm for T2 (p = 0.0003), and 16 mm for T3 (p < 0.0001). The melanoma arose from primary acquired melanosis (T1 = 71%; T2 = 84%; T3 = 81%), preexisting nevus (T1 = 8%; T2 = 5%; T3 = 3%), or de novo (T1 = 21%; T2 = 12%; T3 = 16%). Outcomes at 5 years (Kaplan-Meier) revealed melanoma local recurrence/new tumor in 44% T1, 78% T2 (p < 0.0001), and 76% T3 (P=0.0044); regional lymph node metastasis in 17% T1, 52% T2 (p < 0.0001), and 49% T3 (p = 0.0092); melanoma-related distant metastasis in 11% T1, 35% T2 (p < 0.0001), and 42% T3 (p = 0.0018); and melanoma-related death in 5% T1, 20% T2 (p = 0.0655), and 23% T3 (p = 0.0526). Based on American Joint Committee on Cancer classification, factors predictive of melanoma recurrence included T2 stage (p < 0.0001), and T3 stage (p = 0.0061). After adjusting for tumor origin, factors predictive of regional lymph node metastasis, melanoma-related distant metastasis, and melanoma-related death included melanoma arising de novo (p < 0.0001; p < 0.0001; p < 0.0001), T2 stage (p < 0.0001; p < 0.0001; p = 0.007), and T3 stage (p = 0.005; p = 0.0014; p = 0.0342). CONCLUSION The American Joint Committee on Cancer staging predicts prognosis of conjunctival melanoma. Melanoma classified as T2 and T3 (compared with T1) showed significantly higher rates of local recurrence, regional lymph node metastasis, distant metastasis, and death.
-
topical interferon alfa 2b for management of ocular surface squamous neoplasia in 23 cases outcomes based on american Joint Committee on cancer classification
Archives of Ophthalmology, 2012Co-Authors: Sanket U Shah, Swathi Kaliki, Sara E Lally, Jerry A Shields, Carol L ShieldsAbstract:Objective To evaluate the efficacy of topical interferon alfa-2b in the management of ocular surface squamous neoplasia (OSSN). Methods Clinically visible OSSN in 20 patients (23 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4 times daily. Tumor control and complications were evaluated according to American Joint Committee on Cancer classification. Results Complete tumor resolution was achieved in 19 tumors (83%) following topical interferon alfa-2b treatment for a median period of 6 months (mean, 7 months; range, 1-12 months) and maintained for up to 24 months of follow-up. Of the 4 tumors with partial resolution (17%), tumor surface area was reduced 44% (median) during 4 months (median) without further response and alternative therapy was used. Based on American Joint Committee on Cancer classification, complete control was achieved in 2 of 3 Tis (67%), 17 of 20 T3 (85%), 19 of 23 N0 (83%), and 19 of 23 M0 (83%) category tumors. Tumors involving the cornea responded earlier compared with those without corneal involvement (P = .01). Initial tumor size did not correlate with time to response (P = .27). Recurrence was noted in 1 case (Tis, 4%) at 3 months. Adverse effects included conjunctival hyperemia (2 [10%]), follicular hypertrophy (2 [10%]), giant papillary conjunctivitis (1 [5%]), irritation (1 [5%]), corneal epithelial defect (1 [5%]), and flulike symptoms (1 [5%]); all resolved within 1 month of medication discontinuation. Conclusion According to American Joint Committee on Cancer classification, complete control with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN.
-
American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes.
Ophthalmic plastic and reconstructive surgery, 2012Co-Authors: Carol L Shields, Swathi Kaliki, Sara E Lally, Saad A Al-dahmash, Jerry A ShieldsAbstract:The aim of this study was to evaluate conjunctival melanoma outcomes based on American Joint Committee on Cancer classification. The study design constituted a nonrandomized interventional case series. This was a retrospective chart review comprising 343 participants, and the main outcome measures were melanoma local recurrence, lymph node metastasis, distant metastasis, and death. On the basis of the American Joint Committee on Cancer classification (seventh edition), conjunctival melanoma was classified as T1 (196 [57%]), T2 (110 [32%]), T3 (37 [11%]), and T4 (0). The mean tumor basal diameter increased with tumor staging with 8.5 mm for T1, 12.7 mm for T2 (p = 0.0003), and 16 mm for T3 (p < 0.0001). The melanoma arose from primary acquired melanosis (T1 = 71%; T2 = 84%; T3 = 81%), preexisting nevus (T1 = 8%; T2 = 5%; T3 = 3%), or de novo (T1 = 21%; T2 = 12%; T3 = 16%). Outcomes at 5 years (Kaplan-Meier) revealed melanoma local recurrence/new tumor in 44% T1, 78% T2 (p < 0.0001), and 76% T3 (P=0.0044); regional lymph node metastasis in 17% T1, 52% T2 (p < 0.0001), and 49% T3 (p = 0.0092); melanoma-related distant metastasis in 11% T1, 35% T2 (p < 0.0001), and 42% T3 (p = 0.0018); and melanoma-related death in 5% T1, 20% T2 (p = 0.0655), and 23% T3 (p = 0.0526). Based on American Joint Committee on Cancer classification, factors predictive of melanoma recurrence included T2 stage (p < 0.0001), and T3 stage (p = 0.0061). After adjusting for tumor origin, factors predictive of regional lymph node metastasis, melanoma-related distant metastasis, and melanoma-related death included melanoma arising de novo (p < 0.0001; p < 0.0001; p < 0.0001), T2 stage (p < 0.0001; p < 0.0001; p = 0.007), and T3 stage (p = 0.005; p = 0.0014; p = 0.0342). The American Joint Committee on Cancer staging predicts prognosis of conjunctival melanoma. Melanoma classified as T2 and T3 (compared with T1) showed significantly higher rates of local recurrence, regional lymph node metastasis, distant metastasis, and death.
Omar Abdel-rahman - One of the best experts on this subject based on the ideXlab platform.
-
Assessment of the external validity of the American Joint Committee on Cancer 8th staging system for anal carcinoma.
Current medical research and opinion, 2018Co-Authors: Hani Oweira, Anwar Giryes, Meinrad Mannhart, Michael Decker, Rolf Schlumpf, Omar Abdel-rahmanAbstract:Background: The current study evaluates the prognostic value of the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for patients with anal carcinoma.Patients and methods...
-
Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy.
Therapeutic advances in urology, 2017Co-Authors: Omar Abdel-rahmanAbstract:BackgroundThe objective in this paper was to validate the prognostic performance of the American Joint Committee on Cancer (AJCC) 7th and 8th systems among prostate cancer patients treated with rad...
Swati Singh - One of the best experts on this subject based on the ideXlab platform.
-
Ocular surface squamous neoplasia: analysis based on the 8th American Joint Committee on Cancer classification.
International ophthalmology, 2018Co-Authors: Swati Singh, Ashik Mohamed, Swathi KalikiAbstract:Purpose To evaluate outcomes of ocular surface squamous neoplasia (OSSN) based on American Joint Committee on Cancer (AJCC), 8th edition classification.
Guolian Zhu - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the seventh edition of american Joint Committee on cancer tnm staging system for gastric cancer results from a chinese monoinstitutional study
Annals of Surgical Oncology, 2012Co-Authors: Zhe Sun, Zhenning Wang, Zhi Zhu, Baojun Huang, Guolian ZhuAbstract:Background To investigate the validity of the 7th edition of American Joint Committee on Cancer (AJCC) TNM staging system for gastric cancer with special attention paid to pT2/pT3, pN1/pN2, and pN3a/pN3b category.
